Anika Therapeutics Inc., of Woburn, Mass., named Charles Sherwood president and chief operating officer.
ArQule Inc., of Woburn, Mass., appointed Ariel Elia nonexecutive chairman of the board and Michael Rivard vice president, strategic development.
Atrix Laboratories Inc., of Fort Collins, Colo., added Soe Than as director of medical affairs.
Aviva Biosciences Corp., of San Diego, added Charles Stevens and Richard Cote to its scientific advisory board.
Bio-Technology General Corp., of Iselin, N.J., appointed John Bond senior vice president, finance.
Cell Pathways Inc., of Horsham, Penn., elected Paul Duggan to its board.
Celsion Corp., of Columbia, Md., elected Kris Venkat to its board.
Columbia Laboratories Inc., of New York, added Robert Mills as senior vice president of operations.
CV Therapeutics Inc., of Palo Alto, Calif., appointed Santo Costa and John Groom to its board.
deCODE genetics Inc., of Reykjavik, Iceland, appointed Michael Young vice president of business development.
Discovery Partners International Inc., of San Diego, re-elected Dieter Hoehn and Colin Dollery to its board for three-year terms.
Enanta Pharmaceuticals Inc., of Cambridge, Mass., appointed Andrew Slee vice president of pharmacology.